MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Alsaleh, Ghada ^a,b   Franҫois, Antoine ^a,b   Philippe, Lucas ^a,b   Gong, Ya Zhuo ^a,b   Bahram, Seiamak ^a,b   Cetin, Semih ^a   Pfeffer, Sébastien ^a   Gottenberg, Jacques Eric ^a,b   Wachsmann, Dominique ^a,b   Georgel, Philippe ^a,b   Sibilia, Jean ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; MICRORNA; MICRORNA 30A 3P; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; GAMMA INTERFERON; MIRN30 MICRORNA, HUMAN; POLYINOSINIC POLYCYTIDYLIC ACID;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CELL ISOLATION; CELL STIMULATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS REGULATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYSTEMIC SCLEROSIS; B LYMPHOCYTE; BIOSYNTHESIS; CYTOLOGY; DOWN REGULATION; DRUG EFFECTS; FIBROBLAST; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY;

3' UNTRANSLATED REGIONS; ARTHRITIS, RHEUMATOID; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BASE SEQUENCE; CELL SURVIVAL; DOWN-REGULATION; FEMALE; FIBROBLASTS; HUMANS; INTERFERON-GAMMA; MALE; MICRORNAS; MIDDLE AGED; POLY I-C; SCLERODERMA, SYSTEMIC;

EID: 84910000313     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111266     Document Type: Article

References (43)

1. Mackay F, Schneider P, Rennert P, Browning J (2003) BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21: 231-264. doi:10.1146/annurev.immunol.21.120601.141152.
2. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, et al. (2001) Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97: 198-204.
3. Scapini P, Nardelli B, Nadali G, Calzetti F, Pizzolo G, et al. (2003) G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 197: 297-302.
4. Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, et al. (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201: 195-200. doi:10.1084/jem.20041674.
5. Kalled SL (2005) The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 204: 43-54. doi:10.1111/j.0105-2896.2005.00219.x.
6. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, et al. (1999) Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations. Journal of Experimental Medicine 190: 1697-1710. doi:10.1084/jem.190.11.1697.
7. Seyler TM, Park YW, Takemura S, Bram RJ, Kurtin PJ, et al. (2005) BLyS and APRIL in rheumatoid arthritis. J Clin Invest 115: 3083-3092. doi:10.1172/JCI25265.
8. Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9: 491-502. doi:10.1038/nri2572.
9. Pers J-O, Daridon C, Devauchelle V, Jousse S, Saraux A, et al. (2005) BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 1050: 34-39. doi:10.1196/annals.1313.004.
10. Matsushita T, Hasegawa M, Matsushita Y, Echigo T, Wayaku T, et al. (2007) Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol 16: 87-93. doi:10.1111/j.1600-0625.2006.00485.x.
11. Matsushita T, Fujimoto M, Hasegawa M, Tanaka C, Kumada S, et al. (2007) Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 34: 2056-2062.
12. Zhang M, Ko K-H, Lam QLK, Lo CKC, Srivastava G, et al. (2005) Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis. Int Immunol 17: 1081-1092. doi:10.1093/intimm/dxh287.
13. Alsaleh G, Franc¸ois A, Knapp A-M, Schickel J-N, Sibilia J, et al. (2011) Synovial fibroblasts promote immunoglobulin class switching by a mechanism involving BAFF. Eur J Immunol 41: 2113-2122. doi:10.1002/eji.201041194.
14. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, et al. (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48: 3253-3265. doi:10.1002/art.11299.
15. Chan AC (2011) B cell immunotherapy in autoimmunity-2010 update. Mol Immunol 48: 1344-1347. doi:10.1016/j.molimm.2010.11.021.
16. Chugh PK, Kalra BS (2013) Belimumab: targeted therapy for lupus. Int J Rheum Dis 16: 4-13. doi:10.1111/1756-185x.12002.
17. Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, et al. (2005) Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 120: 623-634. doi:10.1016/j.cell.2004.12.038.
18. Asirvatham AJ, Magner WJ, Tomasi TB (2009) miRNA regulation of cytokine genes. Cytokine 45: 58-69. doi:10.1016/j.cyto.2008.11.010.
19. Philippe L, Alsaleh G, Pichot A, Ostermann E, Zuber G, et al. (2013) MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes. Ann Rheum Dis 72: 1071-1079. doi:10.1136/annrheumdis-2012-201654.
20. Alsaleh G, Suffert G, Semaan N, Juncker T, Frenzel L, et al. (2009) Bruton's tyrosine kinase is involved in miR-346-related regulation of IL-18 release by lipopolysaccharide-activated rheumatoid fibroblast-like synoviocytes. J Immunol 182: 5088-5097. doi:10.4049/jimmunol.0801613.
21. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssière JL, et al. (1995) Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 181: 1661-1672.
22. Alsaleh G, Messer L, Semaan N, Boulanger N, Gottenberg J-E, et al. (2007) BAFF synthesis by rheumatoid synoviocytes is positively controlled by alpha5beta1 integrin stimulation and is negatively regulated by tumor necrosis factor alpha and Toll-like receptor ligands. Arthritis Rheum 56: 3202-3214. doi:10.1002/art.22915.
23. Kishimoto T (2005) Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23: 1-21. doi:10.1146/annurev.immunol.23.021704.115806.
24. Finnegan A, Ashaye S, Hamel KM (2012) B effector cells in rheumatoid arthritis and experimental arthritis. Autoimmunity 45: 353-363. doi:10.3109/08916934.2012.665526.
25. Moisini I, Davidson A (2009) BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol 158: 155-163. doi:10.1111/j.1365-2249.2009.04007.x.
26. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, et al. (2005) Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 174: 864-870.
27. Ittah M, Miceli-Richard C, Gottenberg J-E, Sellam J, Eid P, et al. (2008) Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol 38: 1058-1064. doi:10.1002/eji.200738013.
28. Kato A, Truong-Tran AQ, Scott AL, Matsumoto K, Schleimer RP (2006) Airway epithelial cells produce B cell-activating factor of TNF family by an IFN-beta-dependent mechanism. J Immunol 177: 7164-7172.
29. Zhang S-Y, Jouanguy E, Sancho-Shimizu V, Von Bernuth H, Yang K, et al. (2007) Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol Rev 220: 225-236. doi:10.1111/j.1600-065X.2007.00564.x.
30. Ferraccioli G, Tolusso B (2007) Infections, B cell receptor activation and autoimmunity: different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different immunological settings. Autoimmun Rev 7: 109-113. doi:10.1016/j.autrev.2007.02.013.
31. Ittah M, Miceli-Richard C, Gottenberg J-E, Sellam J, Lepajolec C, et al. (2009) B-cell-activating factor expressions in salivary epithelial cells after dsRNA virus infection depends on RNA-activated protein kinase activation. Eur J Immunol 39: 1271-1279. doi:10.1002/eji.200839086.
32. Mukherji S, Ebert MS, Zheng GXY, Tsang JS, Sharp PA, et al. (2011) MicroRNAs can generate thresholds in target gene expression. Nat Genet 43: 854-859. doi:10.1038/ng.905.
33. Stanczyk J, Pedrioli DML, Brentano F, Sanchez-Pernaute O, Kolling C, et al. (2008) Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 58: 1001-1009. doi:10.1002/art.23386.
34. Ceribelli A, Nahid MA, Satoh M, Chan EKL (2011) MicroRNAs in rheumatoid arthritis. FEBS Lett 585: 3667-3674. doi:10.1016/j.febslet.2011.05.020.
35. Dai Y, Huang Y-S, Tang M, Lv T-Y, Hu C-X, et al. (2007) Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 16: 939-946. doi:10.1177/0961203307084158.
36. Tang Y, Luo X, Cui H, Ni X, Yuan M, et al. (2009) MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 60: 1065-1075. doi:10.1002/art.24436.
37. Li H, Yang R, Fan X, Gu T, Zhao Z, et al. (2012) MicroRNA array analysis of microRNAs related to systemic scleroderma. Rheumatol Int 32: 307-313. doi:10.1007/s00296-010-1615-y.
38. Maurer B, Stanczyk J, Jüngel A, Akhmetshina A, Trenkmann M, et al. (2010) MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 62: 1733-1743. doi:10.1002/art.27443.
39. O'Neill LA, Sheedy FJ, McCoy CE (2011) MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 11: 163-175. doi:10.1038/nri2957.
40. Alsaleh G, Suffert G, Semaan N, Juncker T, Frenzel L, et al. (2009) Bruton's tyrosine kinase is involved in miR-346-related regulation of IL-18 release by lipopolysaccharide-activated rheumatoid fibroblast-like synoviocytes. J Immunol 182: 5088-5097. doi:10.4049/jimmunol.0801613.
41. Semaan N, Frenzel L, Alsaleh G, Suffert G, Gottenberg J-E, et al. (2011) miR-346 controls release of TNF-α protein and stability of its mRNA in rheumatoid arthritis via tristetraprolin stabilization. PLoS ONE 6: e19827. doi:10.1371/journal.pone.0019827.
42. Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, et al. (2013) Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol 40: 579-589. doi:10.3899/jrheum.120886.
43. Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, et al. (2013) Treatment of HCV Infection by Targeting MicroRNA. N Engl J Med. doi:10.1056/NEJMoa1209026.